Amedisys (AMED) Tops Q4 EPS by 6c, Offers FY Guidance

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.91, $0.06 better than the analyst estimate of $0.85. Revenue for the quarter came in at $434.4 million versus the consensus estimate of $427.51 million.

GUIDANCE:

Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.08. Amedisys sees FY2019 revenue of $1.94-1.98 billion, versus the consensus of $1.94 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance
• Rivian raises 2026 delivery outlook after Q2 results top guidance